Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease

Digestion

Volumn 69, Issue SUPPL. 1, 2004, Pages 9-16

  Savarino, Vincenzo ^a,b   Dulbecco, Pietro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Gastro oesophageal reflux disease; GORD complications; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ABDOMINAL PAIN; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPIC THERAPY; ESOPHAGITIS; ESOPHAGUS PH; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; LAPAROSCOPIC SURGERY; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; STOMACH PH; ULCER HEALING;

ADULT; BARRETT ESOPHAGUS; ENDOSCOPY; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS; RECURRENCE;

EID: 1542283688     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076371     Document Type: Conference Paper

References (41)

1. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-1456.
2. Spechler SJ: Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992(suppl 1):24-29.
3. Dent J: Quadrennial review - gastro-oesophageal reflux disease. Digestion 1998;59:433-445.
4. Hirschowitz BI: A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149-1158.
5. Zentilin P, Dulbecco P, Bilardi C, Gambaro C, Iiritano E, Biagini R, Mela GS, Tessieri L, Mele MR, Mansi C, Pandolfo N, Vigneri S, Savarino V: Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD). Aliment Pharmacol Ther 2003;17:353-359.
6. De Caestecker JS, Blackwell JN, Pryde A, Heading RC: Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 1987;28:519-526.
7. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-1447.
8. Bowrey DJ, Clark GWB, Williams GT: Patterns of gastritis in patients with gastro-oesophageal reflux disease. Gut 1999;45:798-803.
9. Zentilin P, Iiritano E, Vignale C, Bilardi C, Mele MR, Spaggiari P, Gambaro C, Dulbecco P, Tessieri L, Reglioni S, Mansi C, Mastracci L, Vigneri S, Fiocca R, Savarino V: Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17:1057-1064.
10. Schwizer W, Thumshirn M, Dent J, Guldenschuh I, Menne D, Cathomas G, Fried M: Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-1742.
11. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-1126.
12. Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Veldhuyzen Van Zanten SJ, Burman CF, Lind T, Wrangstadh M, Bayerdorffer E, Lonovics J: Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002;16:1431-1442.
13. Wolfe MM, Sachs G: Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(suppl 1):S9-S31.
14. Freston JW, Rose PA, Heller CA, Haber M, Jennings D: Safety profile of lansoprazole: the US clinical trial experience. Drug Safety 1999;20:195-205.
15. Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-351.
16. Savarino V, Mela GS, Zentilin P, Bisso G, Pivari M, Vigneri S, Termini R, Fiorucci S, Usai P, Malesci A, Celle G: Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 1998;12:1241-1247.
17. Bell NJV, Burget DW, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
18. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810.
19. Kahrilas P: Gastroesophageal reflux disease. JAMA 1996;276:983-988.
20. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL: Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001;96:3089-3098.
21. Chey W, Huang B, Jackson RL: Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003;23:69-84.
22. Fass R, Ofman JJ: Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002;97:1901-1909.
23. Frazzoni M, De Micheli E, Grisendi A, Savarino V: Lansoprazole vs omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther 2002;16:35-39.
24. Hogan WJ, Shaker R: Medical treatment of supraesophageal complications of gastroesophageal reflux disease. Am J Med 2001;111(suppl 8A):197S-201S.
25. Richter JE, Castell DO: Gastroesophageal reflux: pathogenesis, diagnosis, and therapy. Ann Intern Med 1982;97:93-103.
26. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A: A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110.
27. Robinson M, Lanza F, Avner D, Haber N: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;24:859-867.
28. Talley NJ, Lauritsen K, Tunturi Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-354.
29. Cooper AL, Baxter G: Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003;52(suppl 6):A137.
30. Baldi F, Malfertheiner P: Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003;67:1-5.
31. Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JR, Hislop WS, Theodossi A: A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994;107:1312-1318.
32. Swarbrick ET, Gough AL, Foster CS, Christian J, Garrett AD, Langworthy CH: Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996;8:431-438.
33. Triadafilopoulos G: Proton pump inhibitors for Barrett's oesophagus. Gut 2000;46:144-146.
34. Zentilin P, Conio M, Mele MR, Mansi C, Pandolfo N, Dulbecco P, Gambaro C, Tessieri L, Iiritano E, Bilardi C, Biagini R, Vigneri S, Savarino V: Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther 2002;16:893-898.
35. Sampliner RE, Fennerty B, Garewal HS: Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996;44:532-535.
36. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-338.
37. Spechler SJ: Clinical Practice. Barrett's esophagus. N Engl J Med 2002;346:836-842.
38. Dallemagne B, Weerts JM, Jehaes S, Markiewicz S, Lombard R: Laparoscopic Nissen fundoplication: preliminary report. Surg Laparosc Endosc 1991;1:138-143.
39. Savarino V: Long-term therapy of gastro-oesophageal reflux disease: medical or surgical? Dig Liver Dis 2000;32(suppl 3):S249-S252.
40. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W: Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 2001;285:2331-2338.
41. Ginsberg GG, Barkun AN, Bosco JJ, Burdick JS, Isenberg GA, Nakao NL, Petersen BT, Silverman WB, Slivka A, Kelsey PB: Endoscopic anti-reflux procedures. Gastrointest Endosc 2002;56:625-628.